Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896889997> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2896889997 abstract "Rigors are a significant adverse event during interleukin-2 (IL2) therapy for metastatic melanoma and renal cell carcinoma. Meperidine has been a mainstay for rigor prophylaxis but there is a paucity of data regarding possible alternatives.Ninety one patients receiving IL2 therapy for metastatic renal cell carcinoma and melanoma at Huntsman Cancer institute (HCI), Utah from May 2009 to October 2016 were retrospectively evaluated for rigor prophylaxis. Forty two patients received meperidine and 49 received tramadol. Rigors were tabulated using the proxy of number of doses of as needed (PRN) rigor medications and normalized by IL2 doses. Other outcomes of fever, hypotension, and renal insufficiency were noted on a binary scale and normalized by cycles. Statistical analysis was performed utilizing univariate and multivariate negative binomial models.Ninety one patients were identified with metastatic melanoma or RCC who received high dose IL2 therapy. Forty two received meperidine and 49 received tramadol prophylaxis for rigors. Univariate negative binomial analysis shows incidence rate ratios (IRR): fever 0.41 (95% CI 0.28-0.62, p-value < 0.001), hypotension 1.7 (95% CI 1.11-2.61, p-value 0.015), renal insufficiency 0.58 (95% CI 0.35-0.98, p-value 0.041), rigors per all PRN meds 1.01 (95% CI 0.79-1.28, p-value 0.964), and rigors via opioid PRN meds 0.85 (95% CI 0.67-1.07, p-value 0.168). Multivariate negative binomial analysis shows IRR: fever 0.59 (95% CI 0.28-1.24, p-value 0.163), hypotension 0.93 (95% CI 0.43-2.03, p-value 0.864), renal insufficiency 1.1 (95% CI 0.52-2.32, p-value 0.807), rigors per al PRN meds 0.92 (95% CI 0.67-1.26, p-value 0.604), and rigors via opioid PRN 0.9 (95% CI 0.65-1.26, p-value 0.554).Univariate models indicated meperidine pre-treatment was associated with significantly lower rates of fever and renal insufficiency whereas tramadol was associated with significantly lower rate of hypotension. However, when controlled for demographics and other treatment differences, these differences were no longer significant." @default.
- W2896889997 created "2018-10-26" @default.
- W2896889997 creator A5005395856 @default.
- W2896889997 creator A5007218289 @default.
- W2896889997 creator A5012980257 @default.
- W2896889997 creator A5013307741 @default.
- W2896889997 creator A5013812200 @default.
- W2896889997 creator A5014744153 @default.
- W2896889997 creator A5056451083 @default.
- W2896889997 date "2018-10-20" @default.
- W2896889997 modified "2023-09-29" @default.
- W2896889997 title "Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2" @default.
- W2896889997 cites W1525626036 @default.
- W2896889997 cites W1925498946 @default.
- W2896889997 cites W1950572133 @default.
- W2896889997 cites W1985096500 @default.
- W2896889997 cites W1990004963 @default.
- W2896889997 cites W2080425581 @default.
- W2896889997 cites W2082742146 @default.
- W2896889997 cites W2123914905 @default.
- W2896889997 cites W2139685325 @default.
- W2896889997 cites W2149421501 @default.
- W2896889997 cites W2162553911 @default.
- W2896889997 cites W2335070663 @default.
- W2896889997 cites W52103172 @default.
- W2896889997 doi "https://doi.org/10.1186/s12885-018-4810-y" @default.
- W2896889997 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6195987" @default.
- W2896889997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30342473" @default.
- W2896889997 hasPublicationYear "2018" @default.
- W2896889997 type Work @default.
- W2896889997 sameAs 2896889997 @default.
- W2896889997 citedByCount "2" @default.
- W2896889997 countsByYear W28968899972021 @default.
- W2896889997 countsByYear W28968899972022 @default.
- W2896889997 crossrefType "journal-article" @default.
- W2896889997 hasAuthorship W2896889997A5005395856 @default.
- W2896889997 hasAuthorship W2896889997A5007218289 @default.
- W2896889997 hasAuthorship W2896889997A5012980257 @default.
- W2896889997 hasAuthorship W2896889997A5013307741 @default.
- W2896889997 hasAuthorship W2896889997A5013812200 @default.
- W2896889997 hasAuthorship W2896889997A5014744153 @default.
- W2896889997 hasAuthorship W2896889997A5056451083 @default.
- W2896889997 hasBestOaLocation W28968899971 @default.
- W2896889997 hasConcept C120665830 @default.
- W2896889997 hasConcept C121332964 @default.
- W2896889997 hasConcept C126322002 @default.
- W2896889997 hasConcept C126894567 @default.
- W2896889997 hasConcept C141071460 @default.
- W2896889997 hasConcept C143998085 @default.
- W2896889997 hasConcept C144301174 @default.
- W2896889997 hasConcept C2777472916 @default.
- W2896889997 hasConcept C2777658100 @default.
- W2896889997 hasConcept C2780091579 @default.
- W2896889997 hasConcept C2780227381 @default.
- W2896889997 hasConcept C38180746 @default.
- W2896889997 hasConcept C502942594 @default.
- W2896889997 hasConcept C61511704 @default.
- W2896889997 hasConcept C71924100 @default.
- W2896889997 hasConceptScore W2896889997C120665830 @default.
- W2896889997 hasConceptScore W2896889997C121332964 @default.
- W2896889997 hasConceptScore W2896889997C126322002 @default.
- W2896889997 hasConceptScore W2896889997C126894567 @default.
- W2896889997 hasConceptScore W2896889997C141071460 @default.
- W2896889997 hasConceptScore W2896889997C143998085 @default.
- W2896889997 hasConceptScore W2896889997C144301174 @default.
- W2896889997 hasConceptScore W2896889997C2777472916 @default.
- W2896889997 hasConceptScore W2896889997C2777658100 @default.
- W2896889997 hasConceptScore W2896889997C2780091579 @default.
- W2896889997 hasConceptScore W2896889997C2780227381 @default.
- W2896889997 hasConceptScore W2896889997C38180746 @default.
- W2896889997 hasConceptScore W2896889997C502942594 @default.
- W2896889997 hasConceptScore W2896889997C61511704 @default.
- W2896889997 hasConceptScore W2896889997C71924100 @default.
- W2896889997 hasIssue "1" @default.
- W2896889997 hasLocation W28968899971 @default.
- W2896889997 hasLocation W28968899972 @default.
- W2896889997 hasLocation W28968899973 @default.
- W2896889997 hasLocation W28968899974 @default.
- W2896889997 hasOpenAccess W2896889997 @default.
- W2896889997 hasPrimaryLocation W28968899971 @default.
- W2896889997 hasRelatedWork W1561426946 @default.
- W2896889997 hasRelatedWork W1944020713 @default.
- W2896889997 hasRelatedWork W2014368823 @default.
- W2896889997 hasRelatedWork W2353641271 @default.
- W2896889997 hasRelatedWork W2443482734 @default.
- W2896889997 hasRelatedWork W2557468672 @default.
- W2896889997 hasRelatedWork W2887565042 @default.
- W2896889997 hasRelatedWork W2891281296 @default.
- W2896889997 hasRelatedWork W3157704015 @default.
- W2896889997 hasRelatedWork W4381939530 @default.
- W2896889997 hasVolume "18" @default.
- W2896889997 isParatext "false" @default.
- W2896889997 isRetracted "false" @default.
- W2896889997 magId "2896889997" @default.
- W2896889997 workType "article" @default.